Navigation Links
Data from Phase 2 Study of Alder Biopharmaceuticals' Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer
Date:12/7/2010

ORLANDO, Fla., Dec. 7, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer (NSCLC).

After 12 weeks of treatment with the anti-inflammatory therapeutic, 58 percent of patients who received ALD518 experienced hemoglobin level increases from less than 11 g/dL to more than 12 g/dL, while no patients receiving placebo experienced this increase. In addition, patients who received ALD518 had an average lean body mass loss of 0.19 kg, compared to an average loss of 1.5 kg in those who received placebo. Additional symptoms of the disease such as fatigue were also reduced in patients who received ALD518.

The data was presented by Michael Schuster, M.D., director of the hematologic malignancy program at Stony Brook University Medical Center, at the annual meeting of the American Society of Hematology. The presentation, titled "Inhibition of Interleukin-6 (IL-6) Reverses Anemia In Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial," took place on Monday, December 6.

"The anemia of chronic disease that is seen in cancer patients is in large part due to IL-6 stimulation of hepcidin, resulting in reduced plasma iron levels," said Dr. Schuster. "Given the recent safety concerns over the use of ESAs, alternative therapeutic approaches that target IL-6, such as ALD518, would be very desirable and could potentially reduce the requirement for transfusions in this patient population."

Randall Schatzman, Ph.D., president and chief executive officer of Alder Biopharmaceuticals, added, "We continue to be encouraged by strong clinical data from ALD518 in the areas of cancer, cancer supportive care and cancer anemia. We look forward to continuing our clinical investigation in these areas in the coming year."

About Alder BiopharmaceuticalsAlder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. ALD518 is an investigational monoclonal antibody to the pro-inflammatory cytokine IL-6 that is being developed by Bristol-Myers Squibb for autoimmune indications. In addition to Bristol-Myers Squibb, partners include Merck and Genmab. For more information, visit www.alderbio.com.Media Contact: Ian Stone or David SchullRusso PartnersTel: +1 619-528-2220ian.stone@russopartnersllc.comdavid.schull@russopartnersllc.com
'/>"/>

SOURCE Alder Biopharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016  "Blood Tests replace ... announced ....." The Diagnostic, Monitoring and Screening ... cancer diagnostics is occurring using in vitro blood ... company with impressive backing, has announced a single ... is moving faster than the market. New technology ...
(Date:12/6/2016)... , Dec. 6, 2016 Diabetes & ... The diabetes and obesity disease cluster is currently dominated ... and type 2 diabetes mellitus (T2DM), and the majority ... quality of products, is attributable to these indications. While ... large market presence, there are a large number of ...
(Date:12/6/2016)... 2016 Anaplastic Oligoastrocytoma - Pipeline Review, ... latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic ... overview of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape. ... forms when two types of cells in the ... number to form a mass. These brain cells ...
Breaking Medicine Technology:
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... Castle ... used in several ways to restore a more youthful appearance to the face. Dr. ... offer Sculptra, along with a variety of other treatments, to rejuvenate and renew the ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Levels of ... brain damage, according to a study appearing online in the journal Radiology. , Heart ... expected to increase significantly due to the rapidly aging population. Damage to both organs ...
(Date:12/7/2016)... ... ... came time to blow out his candles on his 14th birthday, Estefano Reano had only ... team at Joe DiMaggio Children’s Hospital surprised his family with a phone call that made ... , “He was playing at home, when we got the phone call telling us there ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff Hart ... in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is ... for a brain tumor. , Jason Bauer and his family are longtime members ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... insurance and financial planning services to families and business owners in the greater ... on behalf of the Dallas Fallen Officer Foundation. , Established in 2009 by ...
Breaking Medicine News(10 mins):